Jeffrey S. Hatfield insider trades: Vitae Pharmaceuticals (VTAE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jeffrey reports to the SEC
and 2 more companies
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 14, 2016 | VTAE | ↓ Sell | 50,000 | $20.81 | $1.0M | Direct | Sep 16, 2016 (2d) |
| Dec 23, 2015 | VTAE | ↓ Sell | 22,524 | $17.00 | $383K | Direct | Dec 28, 2015 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Jeffrey S. Hatfield's insider trades
Jeffrey S. Hatfield is Chief Executive Officer at Vitae Pharmaceuticals (VTAE). Since Dec 23, 2015, Jeffrey has reported no open-market purchases and 2 sales worth $1.4M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (26 filings), option exercises (3 filings), shares returned to the company (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VTAE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.